193 related articles for article (PubMed ID: 35896965)
1. Assessment of unvaccinated and vaccinated patients with coronavirus disease 2019 (COVID-19) treated with monoclonal antibodies during the delta wave (July 1-August 20, 2021): a retrospective observational monocentric study.
Guo Y; Cowman K; Chang M; Bao H; Golia A; Mcsweeney T; Bard L; Simpson R; Andrews E; Pirofski LA; Nori P
BMC Infect Dis; 2022 Jul; 22(1):645. PubMed ID: 35896965
[TBL] [Abstract][Full Text] [Related]
2. Casirivimab/imdevimab treatment for outpatient COVID-19 during a SARS-CoV-2 B1.617.2 (Delta) surge at a community hospital.
Keshishian E; Kuge E; Memmott J; Hasenbalg P; Belford N; Matlock A; Schritter S; Agbayani G; Dietrich T; Santarelli A; Ashurst J
J Osteopath Med; 2022 Dec; 122(12):635-640. PubMed ID: 36123325
[TBL] [Abstract][Full Text] [Related]
3. Impact of COVID vaccine and comorbidities in patients receiving casirivimab-imdevimab monoclonal antibody during SARS-CoV-2 B.1.617.2 (Delta) surge: A real-world study.
Agrawal P; Damania D; Cseh A; Grab J; Strom L; Frank B; Patel D; Clyatt G
Vaccine; 2023 Aug; 41(35):5195-5200. PubMed ID: 37451874
[TBL] [Abstract][Full Text] [Related]
4. Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge.
Bierle DM; Ganesh R; Razonable RR
J Clin Virol; 2021 Dec; 145():105026. PubMed ID: 34775142
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness Trial.
Huang DT; McCreary EK; Bariola JR; Minnier TE; Wadas RJ; Shovel JA; Albin D; Marroquin OC; Kip KE; Collins K; Schmidhofer M; Wisniewski MK; Nace DA; Sullivan C; Axe M; Meyers R; Weissman A; Garrard W; Peck-Palmer OM; Wells A; Bart RD; Yang A; Berry LR; Berry S; Crawford AM; McGlothlin A; Khadem T; Linstrum K; Montgomery SK; Ricketts D; Kennedy JN; Pidro CJ; Nakayama A; Zapf RL; Kip PL; Haidar G; Snyder GM; McVerry BJ; Yealy DM; Angus DC; Seymour CW
JAMA Netw Open; 2022 Jul; 5(7):e2220957. PubMed ID: 35834252
[TBL] [Abstract][Full Text] [Related]
6. Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19.
McCreary EK; Bariola JR; Wadas RJ; Shovel JA; Wisniewski MK; Adam M; Albin D; Minnier T; Schmidhofer M; Meyers R; Marroquin OC; Collins K; Garrard W; Berry LR; Berry S; Crawford AM; McGlothlin A; Linstrum K; Nakayama A; Montgomery SK; Snyder GM; Yealy DM; Angus DC; Kip PL; Seymour CW; Huang DT; Kip KE
JAMA Netw Open; 2022 Apr; 5(4):e226920. PubMed ID: 35412625
[TBL] [Abstract][Full Text] [Related]
7. Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19.
Jabr R; Khatri A; Anderson AD; Garcia LC; Viotti JB; Natori Y; Raja M; Camargo JF; Morris MI
Transpl Infect Dis; 2023 Feb; 25(1):e14006. PubMed ID: 36704987
[TBL] [Abstract][Full Text] [Related]
8. Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.
Razonable RR; O'Horo JC; Challener DW; Arndt L; Arndt RF; Clune CG; Culbertson TL; Hall ST; Heyliger A; Jackson TA; Kennedy BD; Larsen J; Hanson SN; Sweeten PW; Tulledge-Scheitel SM; Ganesh R
Mayo Clin Proc; 2022 Sep; 97(9):1641-1648. PubMed ID: 36058578
[TBL] [Abstract][Full Text] [Related]
9. Outpatient Use of Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Mild-to-Moderate Coronavirus Disease 2019.
Buonomo AR; Filippo ID; Esposito N; Saccone G; Nobile M; Viceconte G; Villari R; Carlo CD; Bifulco G; Gentile I
Am J Perinatol; 2024 Feb; 41(3):365-367. PubMed ID: 37072016
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Monoclonal Antibody Infusion Treatment During Delta (B.1.617.2) and Omicron (B.1.1.529) COVID 19 Variant Surges among Vaccinated and Unvaccinated Patients.
Ghazanfar H; Haider A; Gurjar H; Hernandez N; Jyala A; Bhatt T; Zeana C; Chilimuri S
Health Serv Insights; 2022; 15():11786329221127153. PubMed ID: 36186738
[TBL] [Abstract][Full Text] [Related]
11. Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic.
Suzuki Y; Shibata Y; Minemura H; Nikaido T; Tanino Y; Fukuhara A; Kanno R; Saito H; Suzuki S; Ishii T; Inokoshi Y; Sando E; Sakuma H; Kobayashi T; Kume H; Kamimoto M; Aoki H; Takama A; Kamiyama T; Nakayama M; Saito K; Tanigawa K; Sato M; Kanbe T; Kanzaki N; Azuma T; Sakamoto K; Nakamura Y; Ohtani H; Waragai M; Maeda S; Ishida T; Sugino K; Tsukada Y; Yamada R; Sato R; Onuma T; Tomita H; Saito M; Watanabe N; Rikimaru M; Kawamata T; Umeda T; Morimoto J; Togawa R; Sato Y; Saito J; Kanazawa K; Iseki K
Int J Med Sci; 2022; 19(5):834-841. PubMed ID: 35693744
[No Abstract] [Full Text] [Related]
12. Casirivimab and Imdevimab for Pregnant Women Hospitalized for Severe Coronavirus Disease 2019.
Riccardo BA; Gabriele S; Nunzia E; Isabella DF; Biagio P; Maria F; Emanuela Z; Agnese G; Nicola SM; Giulio V; Riccardo S; Giuseppe B; Ivan G
Am J Perinatol; 2024 May; 41(S 01):e612-e616. PubMed ID: 35973799
[TBL] [Abstract][Full Text] [Related]
13. Noninferiority of Subcutaneous Versus Intravenous Casirivimab/Imdevimab for Outpatient Treatment of SARS-CoV-2 in a Real-World Setting.
Belote A; Reece S; Robinson S; Jensen H; CarlLee S; Clark M; Parnell S; Geels C; Newton J
Monoclon Antib Immunodiagn Immunother; 2022 Aug; 41(4):210-213. PubMed ID: 35920868
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant.
Miyashita N; Nakamori Y; Ogata M; Fukuda N; Yamura A; Ishiura Y
J Infect Chemother; 2022 Sep; 28(9):1344-1346. PubMed ID: 35637130
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Coronavirus Disease 2019 (COVID-19).
Mayer C; VanHise K; Caskey R; Naqvi M; Burwick RM
Obstet Gynecol; 2021 Dec; 138(6):937-939. PubMed ID: 34583385
[TBL] [Abstract][Full Text] [Related]
16. Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant.
Cicchitto G; Cardillo L; de Martinis C; Sabatini P; Marchitiello R; Abate G; Rovetti A; Cavallera A; Apuzzo C; Ferrigno F; Fusco G
Viruses; 2022 Mar; 14(3):. PubMed ID: 35337057
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19.
Arimura K; Tagaya E; Kikuchi K; Mitsuda T; Ebihara F; Maruyama T; Hamada Y; Unagami K; Kanzawa T; Sekiguchi H; Shimamoto K; Ishida H; Egawa H; Tanaka J; Kawana M
Transpl Immunol; 2023 Apr; 77():101777. PubMed ID: 36584927
[TBL] [Abstract][Full Text] [Related]
18. Breakthrough COVID-19 after SARS-CoV-2 vaccination in solid organ transplant recipients: An analysis of symptomatic cases and monoclonal antibody therapy.
Yetmar ZA; Bhaimia E; Bierle DM; Ganesh R; Razonable RR
Transpl Infect Dis; 2022 Apr; 24(2):e13779. PubMed ID: 34932874
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 Neutralizing Monoclonal Antibodies for the Treatment of COVID-19 in Kidney Transplant Recipients.
Wang AX; Busque S; Kuo J; Singh U; Röeltgen K; Pinsky BA; Chertow GM; Scandling JD; Lenihan CR
Kidney360; 2022 Jan; 3(1):133-143. PubMed ID: 35368573
[TBL] [Abstract][Full Text] [Related]
20. Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19 : A Cohort Study.
Kip KE; McCreary EK; Collins K; Minnier TE; Snyder GM; Garrard W; McKibben JC; Yealy DM; Seymour CW; Huang DT; Bariola JR; Schmidhofer M; Wadas RJ; Angus DC; Kip PL; Marroquin OC
Ann Intern Med; 2023 Apr; 176(4):496-504. PubMed ID: 37011399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]